Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ankur Shah

Clinical Cardiac Electrophysiology Columbus, OH Medical Doctor

NPI 1013332857 CMS profile 4216679

3705 Olentangy River Rd Ste 100, Columbus, OH 43214

Open in the dashboard

General payments

$74,803

420 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ankur Shah of Columbus, OH is reported in the CMS Open Payments database as having received $74,803 across 420 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,459 72
2024 General $11,350 87
2023 General $9,813 82
2022 General $6,846 71
2021 General $13,061 16
2020 General $20,050 33
2019 General $5,223 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ankur Shah
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Ankur Shah were reported at $8,459. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Ankur Shah Clinical Cardiac Electrophysiology median Middle half National median
2019 $5,223 $2,361 $585–$8,260 $163
2020 $20,050 $993 $247–$4,351 $114
2021 $13,061 $1,185 $326–$4,739 $132
2022 $6,846 $2,073 $554–$6,789 $149
2023 $9,813 $2,568 $759–$8,159 $160
2024 $11,350 $2,557 $703–$7,403 $164
2025 $8,459 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $24,100 113 payments
  2. Boston Scientific Corporation $17,994 135 payments
  3. Medtronic Vascular, Inc. $14,126 17 payments
  4. Abbott Laboratories $12,733 79 payments
  5. Biosense Webster, Inc. $3,151 29 payments
  6. Biotronik Inc. $465 2 payments
  7. AstraZeneca Pharmaceuticals LP $323 7 payments
  8. Amgen Inc. $313 11 payments
  9. Medical Device Business Services, Inc. $185 2 payments
  10. Edwards Lifesciences Corporation $176 1 payment
  11. Other $1,238 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $29,393 5 payments
  2. Travel and Lodging $22,265 103 payments
  3. Food and Beverage $19,301 304 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,125 2 payments
  5. Education $719 6 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $3,297 30 payments
  2. Micra $2,733 24 payments
  3. AVEIR Cardiac Rhythm Management $2,570 12 payments
  4. THERAPIES $2,514 10 payments
  5. FARAPULSE $1,464 6 payments
  6. General - Therapies General - Therapies_CRM $1,362 7 payments
  7. ENSITE $1,261 12 payments
  8. General - Therapies General - Therapies_EP $1,250 1 payment
  9. WATCHMAN Access System $1,246 11 payments
  10. AVEIR Structural Heart $1,221 13 payments
  11. Other $12,321 200 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,349

Median for Internal Medicine: 777

Drug cost

$451,875

Median for Internal Medicine: $73,373

Branded share of claims

36.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 210 $229,627
Xarelto Rivaroxaban Brand 185 $197,012
Flecainide Acetate Generic 225 $7,745
Dofetilide Generic 26 $7,086
Metoprolol Succinate Generic 261 $2,975
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 54 $2,254
Propafenone Hcl Er Propafenone Hcl Brand 13 $1,765
Amiodarone Hcl Generic 88 $1,076
Sotalol Sotalol Hcl Brand 27 $753
Pantoprazole Sodium Generic 48 $311

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$197,391

Medicare's payments for the services billed

Medicare patients

1,725

Average age 77

Services billed

3,215

726 women, 999 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 64%
Ischemic heart disease 54%
Arthritis 52%
Heart failure 48%
Chronic kidney disease 39%
Diabetes 38%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

420 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record